Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Collaborations
Collaboration to develop ophthalmic therapeutics built from synergistic drug combinations
February 27th, 2006
CombinatoRx, Inc., (CRXX) and Fovea Pharmaceuticals, SA, announced a collaboration for the potential development and commercialization of combination drugs to treat ophthalmic diseases. The agreement unites CombinatoRx's focus on the systematic discovery of combination drug candidates with Fovea's drug-development resources and expertise in the field of ophthalmic therapeutics. "Fovea is dedicated to creating the next generation of drugs to treat disorders of the eye and we look forward to working with their development team to advance CombinatoRx's product candidates into the ophthalmic space," said Alexis Borisy, president and CEO of CombinatoRx....
Source: Pharma Business Week (2006-02-27)
|
